Dr Vink is a well-known and active member of the European and North American life sciences community. In 2012, Dr Vink joined Cubist Pharmaceuticals, a company focused on developing new antibiotics to treat drug-resistant bacterial infections.
At Cubist, he served as Executive Vice President and Chief Operating Officer until the company was bought by Merck for a total transaction value of $9.5 billion in 2015.
Previously, he has held several leadership positions across the pharmaceutical industry, including Senior Vice President, Global head of Hospital Business and Biologics of Mylan (2008-2012), Head of Global Business Franchise Biopharmaceuticals at Novartis Sandoz (2002-2006), Vice President of International Business at Biogen (2000-2002) and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi (1997-2000).
Dr Vink also was a member of the executive committee of the European Federation of Pharmaceutical Industries and Associations between 2013 and 2015. He is currently active as an adviser to the life sciences sector and serves on the board of directors of several companies including Acacia Pharma, Concordia International Corp, Piqur AG and Spero Therapeutics.
Claude Allary, Arch Board Member and former cofounder and Managing Director of Bionest Partners, commented: "Patrick brings a strong industry background, an international network and tremendous experience with antibacterial drugs that will complement our current team, as we move our antibacterial candidate (AB569) to first-in-human trials in 2017."
Adrian Haigh, Arch Board Member and a senior executive of PTC Therapeutics, stated: "We look forward to having Patrick join the Board of Directors, and take an active role in our strategic thinking, and help advise and execute our clinical trials for both AB569 and Metablok."
